Shattuck Labs Reports Second Quarter 2025 Financial Results and Recent Business Highlights

– Submitted Investigational New Drug (IND) application to evaluate SL-325 in a Phase 1 clinical trial in healthy volunteers; clearance expected in Q3 2025 –

– On track to dose first participant in Phase 1 clinical trial for SL-325 in Q3 2025 –

Read more at globenewswire.com